1. We’ve committed to expanding our manufacturing and research footprint coast to coast to continue delivering the medicines our patients need now—and develop new therapies as they advance.
Over the past year, we’ve expanded, broken ground on, and opened new facilities across the US from New Jersey to Texas to California, we are strengthening our manufacturing and R&D footprint and reinforcing our long-term commitment to America’s health.
By localizing our production, we're striving to ensure every key medicine for US patients is made start to finish in the US and bring Novartis’ cutting-edge technology platforms closer to patients – including radioligand therapies, RNA therapeutics, cell and gene therapies.
This phenomenal growth allows us to boost local economies by providing ~1,000 new jobs at Novartis and ~4,000 additional jobs across the US supply chain.
2. From development to delivery, we’re supporting healthier communities through our new Inclusive Health Accelerators (IHA) to close gaps in breast and prostate cancer.
Beyond the investments Novartis is making in US R&D and manufacturing, we are also investing in efforts to connect innovation to community health support for patients across the country. We recently announced the launch of Inclusive Health Accelerator (IHA) initiatives in five cities and their surrounding rural areas— New York City; Los Angeles; Detroit; Baltimore; and Houston.
Building on our long-standing commitment to creating healthier communities worldwide, our new IHA model draws on a powerful combination of data and community insights designed to close critical gaps in breast and prostate cancer care through a holistic, community-first approach.
IHAs connect people to trusted, easy-to-access education, support with post‑screening diagnostic follow‑up and referrals. Each IHA is tailored to the needs of the communities it serves and built in partnership with organizations people already know and trust, including faith groups, community organizations, health centers, and digital health platforms. Together, these partners will help guide individuals through next steps in care so more people can achieve better health outcomes.
Following the launch in breast and prostate cancer this year, we’ll expand across therapeutic areas, into additional US communities, and global markets.
3. We are joining forces with four types of community partners, each with its own area of expertise.
Using a partner-led model for our IHAs, we’ve joined forces with four types of partners, each taking a distinct role in their effort to support communities through:
- Faith-based organizations will help to educate, screen, and navigate the health system.
- Family-focused, hyperlocal community activations for disease awareness, post‑screening diagnostic follow‑up and referrals.
- Academic training for clinicians and health coaches through health systems.
- Technology that helps drive awareness, decision-making, and finding culturally responsive care.
“We take a deliberate approach to partnering with trusted community organizations because they know their communities best and can connect with people in ways traditional healthcare often cannot,” says Korab Zuka, Global Head of Social Impact and Chief Sustainability Officer, Novartis. “Through our IHA model, we aim to help simplify care navigation and help underreached communities gain access to the screenings, follow up care, and support they deserve.”
4. We’re proud to launch in five cities across the US—Houston, New York, Los Angeles, Detroit, and Baltimore, with partnerships focused on breast and prostate cancer education and screening.
Our work to select these cities began with data. We used analytics to identify communities with a high burden of prostate and breast cancer, and the widest gaps in screening, diagnosis and outcomes, and we partnered with trusted local leaders who know the realities their communities face.
We also looked for places where we could meet communities where they are: Where partners are strong, and there is a readiness to work together to improve access and follow-up care. And our model is built to scale — we expect to learn from these early sites and share what works so the model can expand.
Our launch partners are:
The Balm in Gilead, a pioneer in culturally competent public health programs rooted in faith-based partnerships that help strengthen community capacity in health education, disease prevention, screening, and management.
Our partnership will expand access to quality care for people at risk for (or living with) prostate and/or breast cancer and raise awareness about the disease through community education.
African American Male Wellness Agency, is a national leader focused on closing the gap between Black communities and access to critical health services and support, reducing health disparities among Black men and their families. The organization provides free health screenings, culturally relevant health education, and holistic wellness programs in more than 20 US cities.
Together, we’ll elevate their national Get Checked Out, Not Checked In campaign to bring free, community-based health activations to areas disproportionately affected by poor health outcomes. We hope to raise awareness around preventable conditions, reduce systemic barriers to accessing care, and improve health outcomes.
BlackDoctor, the most trusted health and wellness platform for Black Americans, to deliver a community-focused breast and prostate cancer education and navigation program that guides community members along the patient journey from awareness to action.
Our efforts will include family-centered storytelling, outreach by trusted community members, and local events. We’ll also leverage BlackDoctor's Search Tool to connect communities to high-quality, culturally responsive healthcare.
The Weitzman Institute, a nationally recognized leader in continuing education for the primary care workforce. We’ll launch a multi-year initiative designed to measurably increase breast and prostate cancer screening and diagnostic follow-up among medically underserved and rural populations.
We aim to strengthen clinical systems and workflows, enhance provider capacity through integrated training and coaching, empower patients with education and support, and drive measurable improvement through data-driven approaches.
These continued investments in American healthcare build on our legacy as an innovative medicines company. Reflecting our commitment to the patient communities we serve, our national campaign Your Attention Please, and our first-of-its-kind partnership with the NFL work to advance breast and prostate cancer awareness, early detection, and testing — reinforcing our ongoing efforts to help improve health outcomes.
Now, we continue to go further with new community-focused partners until the people facing the greatest barriers have a clear, trusted bridge to the care they deserve.
To learn more about how we’re investing in the US, visit Investing in America’s Health.
